An interaction between warfarin and cannabidiol, a case report

Epilepsy and Behavior Case Reports

Volumn 9, Issue , 2018, Pages 10-11

  Grayson, Leslie ^a   Vines, Brannon ^a   Nichol, Kate ^b   Szaflarski, Jerzy P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b GW Pharmaceuticals Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; LAMOTRIGINE; LEVETIRACETAM; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MARFAN SYNDROME; MITRAL VALVE REPLACEMENT; MONOTHERAPY; ONSET AGE; PRIORITY JOURNAL;

EID: 85042705984     PISSN: 22133232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ebcr.2017.10.001     Document Type: Article

References (11)

1. Szaflarski, J.B., Bebin, E.M., Cannabis, cannabidiol, and epilepsy — from receptors to clinical response. Epilepsy Behav 41:December 2014 (2014), 277–282.
2. Friedman, D., Devinsky, O., Cannabinoids in the treatment of epilepsy. N Engl J Med 373:11 (2015), 1048–1058.
3. Gaston, T.E., et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 58:9 (2017), 1586–1592.
4. Geffrey, A.L., et al. Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56:8 (2015), 1246–1251.
5. Johnson, J.A., et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther, 2017 (n/a-n/a).
6. Coumadin Product Data- FDA.
7. Whirl-Carrillo, M., EMM, Hebert, J.M., Gong, L., Sangkuhl, K., Thorn, C.F., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:4 (2012), 414–417.
8. Wadelius, M., Chen, L.Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. J Pharm 5:4 (2005), 262–270.
9. Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., Watanabe, K., Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:5–6 (2011), 165–170.
10. Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., Watanabe, K., Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88:15–16 (2011), 730–736.
11. Yamaori, S., Koeda, K., Kushihara, M., Hada, Y., Yamamoto, I., Watanabe, K., Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet 27:3 (2012), 294–300.